Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioMarin Buys LEAD Therapeutics of California and Shanghai

publication date: Feb 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioMarin Pharmaceutical of Novato, California, will acquire LEAD Therapeutics of San Bruno, California and Shanghai, a drug discovery company that has a strategic relationship with  ShangPharma, a CRO. ShangPharma has a scientific staff dedicated to doing LEAD’s chemistry work, and it has made an investment in ShangPharma. BioMarin will pay $18 million upfront and an additional $11 million when LEAD’s key compound files for IND. The deal could ultimately be worth $96 million with milestones. More details...

Stock Symbol: (NSDQ: BMRN)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...